Experts across the globe point to the harms of drug companies’ influence on research, practice, and education in healthcare noting that it compromises patient care.
A new study reports that the supplement EPA improved ADHD symptoms but a closer look calls these results into question.
When it comes to ADHD, some researchers suggest that medical textbooks provide inaccurate and misleading information.
Despite their finding, the researchers suggest that SSRIs be given to people who do not meet criteria for depression or anxiety.
: A new review finds evidence of spin and the misrepresentation of clinical trials with non-significant results.
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
Qualitative study examines patterns in teacher attitudes and knowledge related to medication of students for ADHD-type behaviors.
Research illustrates privacy concerns with how mental health applications collect and share users’ data.
Akansha Vaswani interviews Dr. John Read about the influences on his work and his research on madness, psychosis, and the mental health industry.
Industry-funded continuing medical education (CME) influences physicians to prescribe more opioids, focus less on the consequences.
A new study casts doubt on whether such biotypes for depression exist.
Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.
Twice as many teenagers with ADHD experienced severe psychosis when taking Adderall, as compared to Ritalin, according to a new study.
A new study investigated whether participants guessing if they have an antidepressant or placebo affects response rates.
The candidate-gene approach to depression goes unsupported and is likely based on bad science, new research finds.
Dr. Gail Hornstein, author of Agnes’s Jacket: A Psychologist’s Search for the Meanings of Madness, discusses the importance of personal narratives and service-user activism in the context of the global mental health movement.
The latest issue of the journal Behavioral and Brain Sciences features several prominent researchers arguing that mental health concerns are not “brain disorders.”
Researchers examine psychiatrist-client interactions and find that clients are often left with few opportunities to make explicit requests to change their medication regimen.
A new article in Lancet Psychiatry finds that slower tapering of SSRIs is better for preventing antidepressant withdrawal effects.
New research points to numerous harmful effects of high-level lead exposure in childhood on adult mental health and personality characteristics.
John Ioannidis, a leading expert on research methods, takes a critical look at the way professional societies write treatment guidelines.
Dr. Dainius Pūras argues that the status quo in mental health treatment is no longer acceptable and demands political action to promote human rights.
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
Individuals diagnosed with a psychotic disorder are 4-6 times more likely than the general population to experience victimization.
Researchers challenge the recommendation of starting two antidepressants simultaneously to increase preventative effects against suicide.